Volume | 67,172 |
|
|||||
News | - | ||||||
Day High | 65.60 | Low High |
|||||
Day Low | 64.59 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
ANI Pharmaceuticals Inc | ANIP | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
64.59 | 64.59 | 65.60 | 65.36 | 64.95 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
3,967 | 67,172 | $ 65.34 | $ 4,388,815 | - | 36.99 - 70.81 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:29:45 | 38 | $ 67.31 | USD |
ANI Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.38B | 21.08M | - | 486.82M | 17.15M | 0.81 | 80.18 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
ANI Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ANIP Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 64.95 | 66.90 | 64.20 | 65.52 | 110,978 | -2.60 | -4.00% |
1 Month | 69.02 | 69.05 | 64.20 | 66.62 | 140,233 | -6.67 | -9.66% |
3 Months | 55.79 | 70.81 | 54.62 | 65.54 | 148,137 | 6.56 | 11.76% |
6 Months | 58.99 | 70.81 | 48.14 | 59.19 | 156,495 | 3.36 | 5.70% |
1 Year | 37.32 | 70.81 | 36.99 | 56.89 | 155,367 | 25.03 | 67.07% |
3 Years | 32.225 | 70.81 | 22.31 | 46.42 | 118,969 | 30.13 | 93.48% |
5 Years | 69.79 | 86.96 | 22.31 | 48.74 | 114,790 | -7.44 | -10.66% |
ANI Pharmaceuticals Description
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Propafenone, and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States. |